COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today announced that the FDA has provided the Company with positive guidance at a Type C Chemistry Manufacturing and Controls (“CMC”) meeting recently held at the FDA’s Office of New Drug Quality Assessment.
